Metástasis hepáticas en cáncer colorrectal:Situación en el Hospital Central de la Defensa “Gómez Ulla” entre los años 2012 y 2017

  1. P Picaporte Fuentes
  2. J Baquedano Rodríguez
  3. F Fernández Bueno
  4. C Gutiérrez Ortega
  5. A Sánchez Vélez
Journal:
Sanidad militar: revista de sanidad de las Fuerzas Armadas de España

ISSN: 1887-8571

Year of publication: 2019

Volume: 75

Issue: 2

Pages: 80-85

Type: Article

More publications in: Sanidad militar: revista de sanidad de las Fuerzas Armadas de España

Abstract

Colorectal cancer is the most common malignant affection of the intestine. Liver metastases due to colorrectal cancer are the most frequent, being decisive for the survival of these patients. Nearly 25% of the patients have metastases at the time of the diagnosis (synchronous metastases). More than 30% will develop them during their follow-up (metachronous metastases). Ergo, between 55-60% will manifest metastases during the progression of their disease, usually in three years. Purpose: Review the frequency of liver metastases in patients with colorectal cancer who had been diagnosed at the “Gómez Ulla” military hospital during 2012, 2013 and 2014, tracking them until 2017. Methods: A retrospective longitudinal transversal observational study has been conducted. Patients from General and Digestive Surgery Department diagnosed of colorectal cancer during 2012, 2013 and 2014 have been analyzed, tracking them until 2017 considering the follows-up realized after their surgery. Results: 210 patients have been analyzed. 27 had synchronous liver metastases (13%) and 25 had metachronous liver metastases (12%). Conclusions: Despite the non-significant sample size, results show that the percentage of synchronous liver metastases at our hospital (12%) is smaller than the percentage reflected by the scientific knowledge (25%). The bibliography shows that more than 30% of the patients develop metachronous liver metastases. At our hospital, results showed than only 12% develop metachronous liver metastases. That means we have a smaller amount of liver metastasis.